- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | European VC firms band together to tackle continent's lacklustre capital | ||
| Fr | Preclinical model drawbacks dampen UK innovation, ABPI report says | ||
| Fr | Ampersand Capital acquires Purna Pharmaceuticals | ||
| Fr | Amgen receives EC approval for Uplizna in generalised myasthenia gravis | ||
| Do | Sanofi replaces CEO Paul Hudson with outgoing Merck KGaA head | ||
| Do | Madrigal expands MASH pipeline in $4.4bn siRNA licensing deal | ||
| Do | Citius Oncology and Uniphar sign European distribution deal for Lymphir | ||
| Do | MSD receives FDA approval for Keytruda combo to treat ovarian cancer | ||
| Mi | Mexico enlists Moderna to boost mRNA supply for respiratory diseases | ||
| Mi | FDA declines to review Moderna's seasonal flu mRNA vaccine | ||
| Mi | Gilead expects 6% of HIV sales growth in 2026, with $800m Yeztugo target | ||
| Mi | THX Pharma and Biocodex sign licensing deal for Batten-1 and TX01 drugs | ||
| Mi | Insilico and CMS launch drug discovery collaborations for CNS diseases | ||
| Di | AstraZeneca bets on continued oncology demand for 2026 growth | ||
| Di | REGENXBIO receives FDA response for RGX-121 application | ||
| Di | Takeda and Iambic announce $1.7bn deal to advance small molecule programmes | ||
| Mo | Eli Lilly bets on in vivo cell therapy in $2.4bn Orna Therapeutics buyout | ||
| Mo | Novo sues Hims & Hers despite Wegovy pill offering U-turn | ||
| Mo | Innovent and Lilly to advance new oncology and immunology medicines | ||
| Mo | Novartis starts construction on new research facility in San Diego, US | ||
| 06.02. | TrumpRx launches to slash drug prices for cash-paying US patients | ||
| 06.02. | FDA targets illegal drug copies amid latest Hims & Hers/Novo Nordisk flashpoint | ||
| 06.02. | £1bn London Cancer Hub extension gets go-ahead amid UK life sciences push | ||
| 06.02. | BMS reports flat revenue growth for full-year 2025 | ||
| 06.02. | Apotex and Grünenthal sign deal for Nebido Canadian distribution |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.